Cocrystal Pharma completes $4M equity offering priced ATM
- Cocrystal Pharma (NASDAQ:COCP) has announced the completion of a private placement of 2.03M shares of common stock at a price of $1.97/share for proceeds of $4M.
- Through this private placement Dr. Frost has increased his holdings and we welcome Mr. Hassan as a new shareholder,” said James Martin, co-CEO and CFO.
- Cocrystal is also preparing to file with the Australian regulatory agency to begin a first-in-human trial in its oral COVID-19 program with its novel, broad-spectrum protease inhibitor CDI-988.
- The Company also expects to select a lead oral candidate in its norovirus program by mid-2023.
- COCP +12.95% premarket to $2.18.